Study Finds Higher Incidence of Atrial Fibrillation With Ibrutinib Therapy
Patients with chronic lymphocytic leukemia who are treated with ibrutinib may have a higher incidence of atrial fibrillation than previously thought.
Chronic Lymphocytic Leukemia News
CHRONIC LYMPHOCYTIC LEUKEMIA ADVISOR
Chronic Lymphocytic Leukemia News
When COVID-19 Meets CLL: Limited Evidence Offers Some Hope for Good Outcomes
A recent small study is hypothesis generating and highlights the need for COVID-19-related studies with large cohorts of CLL patients.
Results of GO-CLLEAR Study in Patients With Chronic Lymphocytic Leukemia
Investigators compare efficacy and safety of obinutuzumab/chlorambucil, rituximab/ chlorambucil, and rituximab/bendamustine as frontline CLL treatments.
Does Acalabrutinib Improve Outcomes in Relapsed/Refractory CLL?
For patients with r/r CLL, acalabrutinib significantly improved progression-free survival compared with idelalisib-rituximab or bendamustine-rituximab.
Chemotherapy-Free Regimen Consisting of 3 Novel Agents for Previously Untreated, Poor Prognosis CLL
In this study, obinutuzumab, ibrutinib, and venoclax were administered as first-line therapy in patients with CLL characterized by del(17p) and/or TP53 mutation.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Long-Term Outcomes Remain Favorable With Venetoclax-Obinutuzumab
Patients with previously untreated CLL with comorbidities continued to experience greater benefits with venetoclax-obinutuzumab compared with chlorambucil-obinutuzumab.
Early-Memory T-Cell Population May Predict CAR-T Efficacy in Several Hematological Malignancies
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
Improved Risk Stratification Models Needed to Predict Baseline Risk of Tumor Lysis Syndrome in Relapsed CLL Treated With Venetoclax
In this study, the incidence of laboratory tumor lysis syndrome was 13% in a cohort of patients with relapsed CLL treated with venetoclax in a “real world” setting.
Durable Long-Term Responses in B-Cell Lymphoma and Chronic Lymphocytic Leukemia After Anti-CD19 CAR T-Cell Therapy
Researchers reported long-term follow up from the first clinical trial of anti-CD19 CAR T cells that revealed responses against lymphoma.
CD19-Targeted CAR-T With Concurrent Ibrutinib in CLL May Be Feasible After Ibrutinib Failure
CAR-T therapy combined with concurrent ibrutinib is well tolerated in patients with relapsed or refractory CLL.
Investigating CAR-T Efficacy Limitations in Chronic Lymphocytic Leukemia
Efficacy limitations of CAR-T therapy in CLL may not be due to defects in the CAR-T product, but rather, to characteristics of the tumor cells.
Study Links DLBCL and CLL Incidence to Race and Ethnicity, Urban Status
The incidence of DLBCL among Hispanic individuals and CLL among non-Hispanic black individuals was associated with urban status.
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Gene Expression Approach Using Residual Cells Feasible for Future CLL Studies
Two extraction and amplification methods for gene expression analyses on residual leukemic cells may improve future studies when working with fewer cells.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Study Findings Support Long-Term Efficacy and Safety of Acalabrutinib in R/R CLL
Based on results of pharmacodynamics analyses, the phase 2 study protocol was amended to only include a 100 mg, twice-daily dosing of acalabrutinib.
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Real-World Outcomes for Patients With CLL Differ in Community Setting
The Connect CLL Registry revealed that real-world treatment outcomes for patients with CLL who were treated in the community setting differed from trial results.
Acalabrutinib as Potential First-Line Therapy for Chronic Lymphocytic Leukemia
Acalabrutinib, administered as monotherapy or in combination with obinutuzumab, may be an effective first-line therapy to improve outcomes in CLL.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
